HRP20050281A2 - Use of 4-pyridylmethyl-phthalazine derivatives for the manufacture of a medicament for the treatment of myelodysplastic syndromes - Google Patents

Use of 4-pyridylmethyl-phthalazine derivatives for the manufacture of a medicament for the treatment of myelodysplastic syndromes

Info

Publication number
HRP20050281A2
HRP20050281A2 HR20050281A HRP20050281A HRP20050281A2 HR P20050281 A2 HRP20050281 A2 HR P20050281A2 HR 20050281 A HR20050281 A HR 20050281A HR P20050281 A HRP20050281 A HR P20050281A HR P20050281 A2 HRP20050281 A2 HR P20050281A2
Authority
HR
Croatia
Prior art keywords
pyridylmethyl
treatment
medicament
manufacture
myelodysplastic syndromes
Prior art date
Application number
HR20050281A
Other languages
English (en)
Croatian (hr)
Inventor
Han Dugan Margaret
List Alan
Original Assignee
Novartis Ag
The Arizona Board Of Regents On Behalf Of The University Of Arizona
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, The Arizona Board Of Regents On Behalf Of The University Of Arizona filed Critical Novartis Ag
Publication of HRP20050281A2 publication Critical patent/HRP20050281A2/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/502Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HR20050281A 2002-09-24 2003-09-23 Use of 4-pyridylmethyl-phthalazine derivatives for the manufacture of a medicament for the treatment of myelodysplastic syndromes HRP20050281A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41317602P 2002-09-24 2002-09-24
PCT/EP2003/010578 WO2004028542A1 (en) 2002-09-24 2003-09-23 Use of 4-pyridylmethyl-phthalazine derivatives for the manufacture of a medicament for the treatment of myelodysplastic syndromes

Publications (1)

Publication Number Publication Date
HRP20050281A2 true HRP20050281A2 (en) 2006-07-31

Family

ID=32043216

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20050281A HRP20050281A2 (en) 2002-09-24 2003-09-23 Use of 4-pyridylmethyl-phthalazine derivatives for the manufacture of a medicament for the treatment of myelodysplastic syndromes

Country Status (22)

Country Link
US (1) US20060128716A1 (https=)
EP (1) EP1545534B1 (https=)
JP (1) JP2006502195A (https=)
KR (1) KR20050074450A (https=)
CN (1) CN100372535C (https=)
AT (1) ATE359789T1 (https=)
AU (1) AU2003299065B2 (https=)
BR (1) BR0314647A (https=)
CA (1) CA2499738A1 (https=)
CR (1) CR7754A (https=)
DE (1) DE60313344T2 (https=)
EC (1) ECSP055700A (https=)
ES (1) ES2285251T3 (https=)
HR (1) HRP20050281A2 (https=)
MX (1) MXPA05003161A (https=)
NO (1) NO20051936L (https=)
PL (1) PL374696A1 (https=)
PT (1) PT1545534E (https=)
RS (1) RS20050228A (https=)
RU (1) RU2353364C2 (https=)
WO (1) WO2004028542A1 (https=)
ZA (1) ZA200502212B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001519366A (ja) * 1997-10-15 2001-10-23 ポーラクス バイオファーマシュティカルズ,インコーポレーテッド ヒ素化合物を用いた、原発性および転移性の腫瘍性疾患を治療するための組成物および方法
EP1922311A2 (en) 2005-09-09 2008-05-21 Brystol-Myers Squibb Company Acyclic ikur inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7132458B2 (en) * 1994-08-10 2006-11-07 Chemaphor Inc. Oxidized carotenoid fractions and ketoaldehyde useful as cell-differentiation inducers, cytostatic agents, and anti-tumor agents
IL115156A (en) * 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
RU2136308C1 (ru) * 1994-11-16 1999-09-10 Жемчугов Владислав Евгеньевич Стимулятор роста костно-мозговых клеток человека
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
WO2000059509A1 (en) * 1999-03-30 2000-10-12 Novartis Ag Phthalazine derivatives for treating inflammatory diseases
AR025068A1 (es) * 1999-08-10 2002-11-06 Bayer Corp Pirazinas sustituidas y piridazinas fusionadas, composicion farmaceutica que las comprenden, uso de dichos compuestos para la manufactura de un medicamentocon actividad inhibidora de angiogenesis
JP5027369B2 (ja) * 1999-12-06 2012-09-19 ガイストリッヒ ファーマ アーゲー 腫瘍を治療する方法

Also Published As

Publication number Publication date
NO20051936L (no) 2005-06-23
WO2004028542A1 (en) 2004-04-08
AU2003299065A1 (en) 2004-04-19
DE60313344T2 (de) 2008-01-03
MXPA05003161A (es) 2005-09-12
RU2353364C2 (ru) 2009-04-27
RS20050228A (sr) 2007-08-03
US20060128716A1 (en) 2006-06-15
ATE359789T1 (de) 2007-05-15
EP1545534B1 (en) 2007-04-18
CA2499738A1 (en) 2004-04-08
ES2285251T3 (es) 2007-11-16
CR7754A (es) 2005-12-02
RU2005112711A (ru) 2006-02-27
ECSP055700A (es) 2005-08-11
BR0314647A (pt) 2005-08-02
PT1545534E (pt) 2007-06-22
DE60313344D1 (de) 2007-05-31
KR20050074450A (ko) 2005-07-18
ZA200502212B (en) 2006-02-22
CN1684684A (zh) 2005-10-19
JP2006502195A (ja) 2006-01-19
PL374696A1 (en) 2005-10-31
EP1545534A1 (en) 2005-06-29
CN100372535C (zh) 2008-03-05
AU2003299065B2 (en) 2006-10-26

Similar Documents

Publication Publication Date Title
EA200700096A1 (ru) Производные 2-карбамид-4-фенилтиазола, способ их получения и их применение в терапии
EA201000643A1 (ru) Замещенное производное этилендиамина для лечения микобактериальных заболеваний и фармацевтическая композиция на его основе
CY1117584T1 (el) Παραγωγα 1-βενζυλ-3-υδροξυμεθυλινδαζολης και η χρηση τους στη θεραπευτικη αντιμετωπιση νοσων που βασιζονται στην εκφραση των mcp-1, cx3cr1
CY1109877T1 (el) Αντισωματα εναντι αμυλοειδους-βητα πεπτιδιου
PL410218A1 (pl) Sposób wytwarzania stabilnej liofilizowanej kompozycji obejmującej monomeryczne koniugaty pochodna kalicheamycyny/przeciwciało anty-CD22, kompozycja otrzymana tym sposobem oraz jej zastosowanie
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
CY1113858T1 (el) Παραγωγα πυριδιν-3-υλιου ως ανοσορυθμιστικοι παραγοντες
EA200802390A1 (ru) Конъюгаты аналогов азиридилэпотилона и фармацевтические композиции, содержащие их
DK1478329T3 (da) Præparat til oral indgivelse tikl beskyttelse af huden mod lys
LU92326I2 (fr) Canakinumab et ses dérivés pharmaceutiquement acceptables (ILARIS)
SMT201200014B (it) Nalmefene cloridrato diidrato.
CY1117504T1 (el) Παραγωγα 1-βενζυλ-3-υδροξυμεθυλινδαζολης και η χρηση τους στη θεραπευτικη αντιμετωπιση νοσων που βασιζονται στην εκφραση των mcp-1, και cx3cr1
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
UY28098A1 (es) Derivados de anilinopirazol útiles en el tratamiento de la diabetes
CY1112451T1 (el) Μεθοδος για μειωση γαστρεντερικης τοξικοτητας λογω της χορηγησης τεγκαφουρης
BRPI0311189B8 (pt) composições farmacêuticas contendo polimorfo a de flibanserin, bem como seu uso
UY28774A1 (es) Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes.
ATE466842T1 (de) 3-substituierte pyridinderivate als h3- antagonisten
MX2007007027A (es) Derivados piperazinilpiridina como agentes anti-obesidad.
SE0300457D0 (sv) Novel compounds
HRP20050281A2 (en) Use of 4-pyridylmethyl-phthalazine derivatives for the manufacture of a medicament for the treatment of myelodysplastic syndromes
ATE413187T1 (de) Pharmazeutische zusammensetzungen mit interferon- tau
UY27628A1 (es) "2'-halo -3',5'-dialcoxi-fen-1'il-2-imidazolidinas y su uso como un fármaco"
CY1106385T1 (el) Χρηση παραγωγων της εποθειλονης για τη θepαπεια του υπepπαραθυρεοειδισμου
NO20054723L (no) Behandling av proliferative sykdommer med epofilonderivater og straling

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20060808

Year of fee payment: 4

ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
OBST Application withdrawn